Article Per Year (5 Year)
p-Index From 2020 - 2025
3.128
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Brawijaya Universa Medicina Jurnal Respirasi (JR) Malang Respiratory Journal Jurnal Klinik dan Riset Kesehatan Journal of Community Health and Preventive Medicine (JOCHAPM)
Pratiwi, Suryanti Dwi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Environmental Science Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 20 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search
Journal : Jurnal Respirasi (JR)

 1 
Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer Santoso, Agus Andreas; Pratiwi, Suryanti Dwi; Sugiri, Yani Jane; Al Rasyid, Harun; Listyoko, Aditya Sri
Jurnal Respirasi Vol. 11 No. 2 (2025): May 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.2.2025.140-146

Abstract

Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This study aimed to determine the effectiveness of epidermal growth factor receptor (EGFR)-TKI based on progression-free survival (PFS) and overall survival (OS) in NSCLC patients with common EGFR mutations. Methods: This retrospective cohort study used a total sampling method. The serum CEA level was measured before the initial treatment. Tyrosine kinase inhibitors therapy was monitored with PFS and OS. Statistical analysis for comparing prognosis in NSCLC among TKI groups used Kruskal-Wallis, analysis of variance (ANOVA), Mann-Whitney, and Spearman’s rho tests. A significant analysis referred to a p-value of <0.05. Results: The participants were 189 patients, consisting of 106 on gefitinib, 43 on erlotinib, and 40 on afatinib. The average PFS values in the gefitinib, erlotinib, and afatinib groups were 9.9±5.25, 8.77±4.53, and 12.83±7.02 months, respectively (p=0.016). Furthermore, there were no significant OS among the gefitinib (14.91±7.61 months), erlotinib (14.54±7.64 months), and afatinib group (15.51±8.13 months, p=0.867). There was a significant correlation between CEA levels and PFS (r=0.146; p=0.046) and between CEA levels and OS (r=0.223; p=0.004). Conclusion: Although afatinib may prolong PFS compared with gefitinib and erlotinib, it did not significantly impact OS. Increased serum CEA levels before treatment significantly improved PFS and OS. However, elevated CEA levels are usually associated with a poor prognosis in NSCLC.
D-Dimer and Brixia Score to Mortality in COVID-19 Patients Falyani, Silvy Amalia; Pratiwi, Suryanti Dwi; Setyawan, Ungky Agus; Erawati, Dini Rachma; Djajalaksana, Susanthy; Listyoko, Aditya Sri
Jurnal Respirasi Vol. 10 No. 2 (2024): May 2024
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v10-I.2.2024.99-106

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is a highly contagious severe and acute respiratory syndrome caused by the SARS-CoV-2 virus. A variety of factors can increase a patient's risk of death, including coagulopathy characterized by increased D-dimer levels. Brixia scores could be one of the determinants of COVID-19 severity, as assessed by chest radiographs. This study aimed to analyze chest radiographic severity based on the Brixia score at the degree of coagulation based on D-dimer in mortality of COVID-19 patients who were hospitalized. Methods: This cohort retrospective study was conducted at Dr. Saiful Anwar General Hospital, Malang, using an observational cross-sectional design. The study included 300 medical records of COVID-19 patients who passed away while hospitalized. The data were analyzed using the Wilcoxon test, and the results were also tested for Spearman correlation to determine the relationship between variables. Results: Significance results of median D-dimer were found by age and severity of COVID-19 (p-values 0.015 and 0.002), and median Brixia scores by age, gender, severity of COVID-19, and length of treatment (p-values 0.001, 0.001, 0.001, and 0.005). The results were also compared with normal values, which were significant (p = 0.000). Spearman correlation test results between the final D-dimer and the initial Brixia score (p = 0.005). Conclusion: The research results display a retrospective study of the correlation between D-dimer and Brixia score values "‹"‹and outcomes in COVID-19 patients. Higher D-dimer values"‹ "‹and Brixia scores on admission were shown to be associated with mortality.
The Effect of Anemia on Prognostic in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy Kartikasari, Ulfah; Pratiwi, Suryanti Dwi; Astuti, Tri Wahju; Setijowati, Nanik
Jurnal Respirasi Vol. 10 No. 2 (2024): May 2024
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v10-I.2.2024.120-129

Abstract

Introduction: Lung cancer has the highest incidence and mortality rate, which contributes to approximately 2.2 million cancer cases (11.4%) of total cancers worldwide. More than 70% of lung cancer cases present in the late, non-operable stage. Anemia is one of the conditions that could precipitate cancers and affect the patient's clinical presentation, including tissue oxygenation, organ function, and quality of life. It could also increase the risk of bleeding, post-operative mortality, and iron absorption rate in the case of ineffective erythropoiesis. All of these could affect the prognostic factor of the cancer. This study aimed to evaluate the effect of the severity of anemia on overall survival (OS) and progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Methods: This was a retrospective cohort study involving 80 subjects of NSCLC patients treated with platinum-based chemotherapy from January 2018 to December 2020. Subjects were divided into two groups (39 patients in the normal group and 41 patients in the anemia group). Results: The mean pre-treatment hemoglobin (Hb) was 10.55 ± 1.25 g/dL in NSCLC patients with anemia. The bone metastasis, OS, and PFS values of the normal and anemia groups were significant (p = 0.008; p = 0.002; p = 0.27). Anemia was significantly related to OS (r = 0.146, p = 0.000) and PFS (r = 0.264, p = 0.000) in NSCLC patients treated with platinum-based chemotherapy. Conclusion: Higher severity of anemia can reduce OS and PFS in NSCLC patients treated with platinum-based chemotherapy.
The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia Syahruddin, Elisna; Soeroso, Noni Novisari; Ananda, Fannie Rizki; Wulandari, Laksmi; Setijadi, Ana Rima; Ermayanti, Sabrina; Pratiwi, Suryanti Dwi; Infianto, Andreas; Andayani, Novita; Munir, Sri Melati; Pratama, Avissena Dutha; Kusumawardani, Ida Ayu Jasminarti Dwi; Haryati, Haryati; Duyen, Natalie; Hanif, Muhammad Alfin; Lim, Darren Wan-Teck
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.22-30

Abstract

Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI. Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression. Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001). Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis.
The Influence of Nigella sativa on the Increase of IFN-γ and Quality of Life in Lung Cancer Patients Undergoing Chemotherapy Mahendra, Reza Aditya; Pratiwi, Suryanti Dwi; Sartono, Teguh Rahayu; Rakhma, Sastia; Setijowati, Nanik
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.31-38

Abstract

Introduction: In vitro and animal model studies have shown that Nigella sativa reduces cancer cell proliferation and improves chemotherapy effectiveness. Cellular activation triggers the production of IFN-γ by natural killer (NK) cells. This study examined the effect of Nigella sativa supplementation on IFN-γ levels and quality of life in lung cancer patients before and after interferon therapy. Methods: This study used a non-equivalent control experimental design involving 21 lung cancer patients undergoing initial chemotherapy at Dr. Saiful Anwar General Hospital, Malang, in 2023. The patients were divided into two groups: one group received standard chemotherapy, and another group received a combination of chemotherapy and Nigella sativa supplementation at a dose of 2x500 mg for nine weeks. The effects of this intervention were assessed by measuring IFN-γ levels using an enzyme-linked immunosorbent assay (ELISA) kit and evaluating quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QLQ-C30) questionnaire before and after the fourth cycle of chemotherapy. Results: The results showed a significant increase in IFN-γ levels in the combination group undergoing chemotherapy and receiving Nigella sativa supplementation (6140.44±2233.89) compared to the standard chemotherapy group (3827.08±1722.79), with a p-value of 0.015. Quality of life improved in both groups, with scores of 53.70±6.05 before and 65.74±14.70 after chemotherapy (p=0.000). Conclusion: This study found that Nigella sativa supplementation can enhance IFN-γ levels and quality of life in lung cancer patients after four chemotherapy treatment cycles. These findings indicated that Nigella sativa could be a beneficial supplement for lung cancer patients.
Co-Authors Ahmad Bayhaqi, Ahmad Ana Rima Setijadi Ananda, Fannie Rizki Aslam, Ahmad Bayhaqi Nasir Asmiragani, Syaifullah Djajalaksana, Susanthy Duyen, Natalie Eka Agustina, Dwi Rosa Elisna Syahruddin Erawati, Dini Rachma Erawati, Rachma Dini Ermayanti, Sabrina Eviana Norahmawati Fahmi, Kristia Falyani, Silvy Amalia Febriawati, Juwita Hanif, Muhammad Alfin hardiyanto, frenky Harun Al Rasyid Harun Al Rasyid Haryati Haryati Hendri Wiyono, Hendri Holipah, Holipah Ida Ayu Jasminarti Dwi Kusumawardani Imam Suseno Infianto, Andreas Isharanto, Artono Kartikasari, Ulfah Kevin Wahyudy Prasetyo Laksmi Wulandari Lim, Darren Wan-Teck Listyoko, Aditya Sri lumban gaol, andy Mahendra, Reza Aditya Maleachi, Reginald Merdekawati, Ratih Dwi ary Naftali, Yokanan Nanik Setijowati Noni Novisari Soeroso Novita Andayani, Novita Permatasari, Adinda Pramitra Pratama, Avissena Dutha Primaputri, Cindy Carrissa Pudjo, Herwindo Putra, Ngakan Putu rahmah, shofi nur Rakhma, Sastia Retnani, Diah Prabawati Rini, Ni Made Santosa, Andrew Santoso, Agus Andreas Sartono, Teguh Rahayu Setyawan, Ungky Agus Sri Andarini Sri Melati Munir Sugiri, Jani Jane Rosihaningsih Sugiri, Yani Jane Sugiri, Yani Jane Rosihaningsih Tri Wahju Astuti, Tri Wahju Widowati, Yenny Yani Jane Yokanan Yudhanto, Hendy Setyo